Jim Cramer discussed Verona Pharma plc (NASDAQ:VRNA) as Merck announced its $10 billion acquisition, boosting shares by 20.6% in July. Cramer called VRNA’s COPD drug a “first in class” compound crucial for Merck’s drug portfolio. He mentioned antitrust approval unlikely to be an issue for the acquisition.

Cramer praised VRNA’s acquisition, highlighting its potential for new drugs worth $50 billion. He believes VRNA’s COPD drug will offset concerns about Keytruda’s patent expiration in 2028, offering a novel compound with reduced side effects. Cramer supports the acquisition, endorsing VRNA as a valuable asset for Merck.

Despite VRNA’s promise, some AI stocks offer higher returns with limited risk. To explore a cheap AI stock benefiting from Trump tariffs and onshoring, check out a free report on the best short-term AI stock. Discover opportunities for growth with 30 stocks expected to double in 3 years and 11 hidden AI stocks to buy now.

Read more at Yahoo Finance: Verona Pharma plc (VRNA) Is Unlikely To Face Antitrust Action For Merck Deal, Says Jim Cramer